S Africa Govt Slams Drug Firms Over AIDS Play Row

22 September 1996

South Africa's government, including President Nelson Mandela, has attacked multinational drug firms and the "white media" after a mystery benefactor who had offered to bail the Health Department out of a financial and political scandal withdrew his offer.

In January, the new government's biggest embarrassment yet revealed that the Department had spent 14.3 billion rand ($3.18 billion), nearly one-third of its annual AIDS awareness budget, on a controversial AIDS awareness play, Sarafina 2. In late 1995, Health Minister Nkosazana Zuma had approached playwright and musician Mbongeni Ngema after the Broadway staging of his successful musical Sarafina with her idea of promoting AIDS awareness through theater. He was awarded the project, for which about 1 million rand was earmarked after an irregular tender procedure, and came up with Sarafina 2.

But after its premier in Durban on World AIDS Day in December 1995, the play was slammed by AIDS experts, health workers and theater managers, especially over the poor, faulty and misleading content of the message, and the price of the tickets. Mr Ngema was ordered to make substantial changes in response to the criticism over the content.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight